Jun 2026 (Q2 FY26) — Aug 6, 2026
Maravai LifeSciences Q2 FY26 — Strong Execution Drives Profitability and Balance Sheet Improvement
Read the full callMaravai LifeSciences (MRVI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Maravai LifeSciences earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 51.4 | +8.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -29.3 | +110.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -12.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$6.99 +2.95% · +$0.2
Performance +111.8% 1Y
1Y: $3.3 on 17 Oct 2025 → $6.99. High $9 (25 Aug 2026), low $2.83 (31 Mar 2026).
- Previous close
- $6.79
- 52-week range
- $2.83 – $9
- One year
- +98.58%
Overview
- Symbol
- MRVI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Maravai LifeSciences earnings calls (MRVI)
Financials
What the filings say
Net profit, year on year: +69% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 57 | 47 | 47 | 42 | 50 | 66 | 51 |
| Expenses | 198 | 94 | 57 | 74 | 47 | 72 | 36 | 36 |
| Operating profit | -166 | -38 | -49 | -66 | -41 | -59 | -2 | -15 |
| Operating margin | −239.9% | −66.7% | −104.9% | −139.8% | −98.6% | −117.9% | −3.3% | −29.3% |
| Interest | 14 | 11 | 7 | 7 | 7 | 7 | 6 | 5 |
| Profit before tax | -172 | -46 | -53 | -74 | -45 | -63 | -7 | -22 |
| Tax rate | −0.2% | 0.0% | −0.3% | 5.8% | 0.2% | −0.0% | 2.3% | 0.8% |
| Net profit | -97 | -26 | -30 | -40 | -26 | -36 | -4 | -12 |
| EPS ($ per share) | -0.68 | — | -0.21 | -0.27 | -0.18 | — | -0.02 | -0.08 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Reserves | — | 1 | 185 | 405 | 286 | 141 | 10 |
| Total liabilities | — | 1,116 | 1,373 | 1,377 | 698 | 431 | 398 |
| Fixed assets | — | 101 | 46 | 53 | 163 | 164 | 151 |
| Total assets | — | 1,271 | 1,918 | 2,282 | 1,487 | 1,008 | 771 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 24 | 152 | 369 | 536 | 126 | 7 | -58 |
| Cash from investing | -17 | 6 | 106 | -268 | -122 | -24 | -31 |
| Cash from financing | -4 | 53 | -159 | -187 | -61 | -236 | -16 |
| Net cash flow | 3 | 211 | 315 | 81 | -57 | -253 | -106 |
| Capital expenditure | -17 | -25 | -15 | -17 | -66 | -30 | -13 |
| Free cash flow | 7 | 127 | 354 | 519 | 61 | -22 | -71 |
Insider filings
32 filings between Nov 11, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
$1.88M
5 purchases by 2 insiders
Sales
$254.0K
2 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
- 13
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Brust Bernd | $1.51M | — | Nov 13, 2025 |
| LUCIER GREGORY T | $368.5K | — | Dec 8, 2025 |
| ORESHACK KURT | — | $254.0K | Jun 10, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Brust Bernd Chief Executive Officer | Tax withheld | 29,250 | $217.3K |
| Sep 30, 2026 | Asarpota Rajesh Chief Financial Officer | Tax withheld | 5,465 | $41.8K |
| Sep 8, 2026 | Brust Bernd Chief Executive Officer | Tax withheld | 29,250 | $214.1K |
| Aug 31, 2026 | Asarpota Rajesh Chief Financial Officer | Tax withheld | 5,465 | $42.0K |
| Aug 10, 2026 | Brust Bernd Chief Executive Officer | Tax withheld | 29,250 | $182.2K |
| Jul 30, 2026 | Asarpota Rajesh Chief Financial Officer | Tax withheld | 5,465 | $36.0K |
| Jul 8, 2026 | Brust Bernd Chief Executive Officer | Tax withheld | 29,250 | $173.2K |
| Jun 30, 2026 | Asarpota Rajesh Chief Financial Officer | Tax withheld | 65,584 | $419.1K |
| Jun 10, 2026 | ORESHACK KURT General Counsel | Sale 10b5-1 plan | 25,000 | $127.5K |
| Jun 9, 2026 | LUCIER GREGORY T Director | Gift | 46,293 | $0 |
| Jun 9, 2026 | ORESHACK KURT General Counsel | Sale 10b5-1 plan | 25,000 | $126.5K |
| Jun 9, 2026 | LUCIER GREGORY T Director | Gift | 46,293 | $0 |
| Jun 8, 2026 | Brust Bernd Chief Executive Officer | Tax withheld | 351,001 | $1.76M |
| May 26, 2026 | MARKER LUKE JOSEPH Director | Award | 46,293 | $0 |
| May 26, 2026 | GRAY SUSANNAH Director | Award | 46,293 | $0 |
| May 26, 2026 | LUCIER GREGORY T Director | Award | 46,293 | $0 |
| May 26, 2026 | CUNNINGHAM SEAN LAURENCE Director | Award | 46,293 | $0 |
| May 26, 2026 | MIHAS CONSTANTINE S Director | Award | 46,293 | $0 |
| May 26, 2026 | ECKERT R ANDREW Director | Award | 46,293 | $0 |
| May 26, 2026 | DeFord John A Director | Award | 46,293 | $0 |
| May 15, 2026 | ORESHACK KURT General Counsel | Award | 776 | $2.2K |
| May 15, 2026 | Dolan Christine See Remarks | Award | 5,006 | $9.0K |
| Mar 16, 2026 | ORESHACK KURT General Counsel | Tax withheld | 39,976 | $123.1K |
| Mar 16, 2026 | Dolan Christine See Remarks | Tax withheld | 28,661 | $88.3K |
| Jan 15, 2026 | Dolan Christine See Remarks | Tax withheld | 28,934 | $106.8K |
| Jan 15, 2026 | ORESHACK KURT General Counsel | Tax withheld | 31,902 | $117.7K |
| Dec 8, 2025 | LUCIER GREGORY T Director | Purchase | 48,528 | $178.1K |
| Dec 5, 2025 | LUCIER GREGORY T Director | Purchase | 51,472 | $190.4K |
| Nov 14, 2025 | Dolan Christine See Remarks | Award | 4,300 | $7.7K |
| Nov 13, 2025 | Brust Bernd Chief Executive Officer | Purchase | 216,212 | $702.7K |
| Nov 12, 2025 | Brust Bernd Chief Executive Officer | Purchase | 93,358 | $299.7K |
| Nov 11, 2025 | Brust Bernd Chief Executive Officer | Purchase | 157,201 | $509.3K |
| Jul 15, 2025 | Leddy Peter Michael See Remarks | Tax withheld | 5,154 | $13.3K |
| Jul 10, 2025 | LUCIER GREGORY T Director | Gift | 89,139 | $0 |
| Jul 10, 2025 | LUCIER GREGORY T Director | Gift | 89,139 | $0 |
| Jun 30, 2025 | Asarpota Rajesh Chief Financial Officer | Award | 500,000 | — |
| Jun 16, 2025 | DAVERMAN BENJAMIN JAMES Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | Hopfield Jessica Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | DeFord John A Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | MIHAS CONSTANTINE S Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | ECKERT R ANDREW Director | Award | 231,481 | $500.0K |
| Jun 16, 2025 | CUNNINGHAM SEAN LAURENCE Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | PRAHALAD MURALI Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | LUCIER GREGORY T Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | MARKER LUKE JOSEPH Director | Award | 89,139 | $192.5K |
| Jun 16, 2025 | GRAY SUSANNAH Director | Award | 89,139 | $192.5K |
| Jun 8, 2025 | Brust Bernd Chief Executive Officer | Award | 2,000,000 | — |
| May 15, 2025 | Herde Kevin Chief Financial Officer | Award | 876 | $1.5K |
| May 15, 2025 | Dolan Christine See Remarks | Award | 2,381 | $4.0K |
| Mar 17, 2025 | Herde Kevin Chief Financial Officer | Tax withheld | 8,648 | $22.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MARAVAI LIFESCIENCES HOLDINGS, INC.
Free account. Everything above stays public.
Write why you follow MARAVAI LIFESCIENCES HOLDINGS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading